Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies, has granted inducement equity awards to 10 new employees. The Compensation Committee approved options to purchase 299,200 shares of common stock under the company's 2020 Inducement Plan on September 29, 2025.

The options feature a 10-year term with a four-year vesting schedule, including 25% vesting after one year and the remainder vesting monthly over 36 months. The exercise price equals Cogent's closing stock price on the grant date, subject to continued employment through vesting dates.

WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that on September 25, 2025, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to 10 new employees under the company’s 2020 Inducement Plan with a grant date of September 29, 2025. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market.

The employees received, in the aggregate, nonqualified options to purchase 299,200 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a four-year vesting schedule with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. 

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

What type of equity awards did Cogent Biosciences (COGT) grant to new employees?

Cogent granted nonqualified options to purchase 299,200 shares of common stock with a 10-year term and four-year vesting schedule.

How many new employees received stock options from Cogent Biosciences?

10 new employees received stock option grants under Cogent's 2020 Inducement Plan.

What is the vesting schedule for Cogent Biosciences' September 2025 inducement grants?

The options vest 25% after one year, with the remaining vesting in equal monthly installments over 36 months, requiring continued employment.

When did Cogent Biosciences' Compensation Committee approve the inducement grants?

The Compensation Committee approved the inducement grants on September 25, 2025, with a grant date of September 29, 2025.